Why Early Detection Matters
Alzheimer’s disease develops over decades. By the time symptoms appear, the window for effective prevention may already be closing. Researchers have long sought ways to identify risk years — or even a decade — before cognitive decline begins. Now, a new Vanderbilt Health study offers a powerful data-driven approach using electronic health records (EHRs).
The study, published in the journal Alzheimer’s Research & Therapy, identifies more than 70 medical conditions that frequently appear in patients before they receive an Alzheimer’s diagnosis. This breakthrough opens the door to earlier clinical intervention and better-targeted prevention strategies.
How Vanderbilt Used EHR Data
Two Massive Databases, One Clear Mission
Researchers at Vanderbilt Health analyzed de-identified EHRs from two independent sources. First, they used MarketScan — a U.S. claims-based database covering more than 150 million individuals — as their discovery cohort. Then, they validated findings using Vanderbilt Health’s own EHR system, which holds records for approximately 3 million patients.
The study included more than 44,000 confirmed Alzheimer’s cases and over 430,000 age- and sex-matched controls across both datasets. Researchers tracked EHR data over a 10-year window preceding each Alzheimer’s diagnosis. By comparing health records between those who later developed the disease and those who did not, they identified medical conditions that appeared more frequently in the Alzheimer’s group.
A 10-Year Lookback Window
This 10-year lookback approach is particularly significant. It means clinicians can potentially spot early warning signs long before memory loss occurs. “If we know the full inventory of medical conditions that predict Alzheimer’s disease development 10 or more years later, we can potentially intervene before clinical symptoms become apparent,” said Xue Zhong, Ph.D., research assistant professor of Medicine at Vanderbilt.
Key Risk Conditions Identified
Mental Health, Metabolic, and Cardiovascular Patterns
The analysis revealed over 70 medical conditions linked to a higher likelihood of developing Alzheimer’s. Several conditions emerged consistently across both datasets. These include:
- Depression — frequently observed years before diagnosis
- Insomnia — a recurring sleep disorder tied to neurological decline
- Hypertension — a well-known cardiovascular risk factor
- Type 2 diabetes — a metabolic condition linked to brain inflammation
- Cerebral atherosclerosis — hardening of brain arteries that restricts blood flow
Notably, the study confirms both hypertension and hypercholesterolemia as significant risk factors for late-life Alzheimer’s disease. These are both manageable conditions. Effectively treating them in midlife may reduce long-term Alzheimer’s risk, which is an encouraging insight for preventive medicine.
A Broad Spectrum of Disorders
Beyond cardiovascular and metabolic conditions, the findings span neurological, sleep-related, and mental health disorders. This wide spectrum highlights that Alzheimer’s risk is not a single-pathway problem. Instead, it reflects complex, intersecting health conditions building up over years.
Genetic Validation Strengthens Findings
Biobank Data Confirms EHR Patterns
To move beyond correlation, the Vanderbilt team validated their EHR findings using genetic data. They drew from two large-scale DNA biobanks: Vanderbilt Health’s own BioVU and the UK Biobank. This genetic layer adds scientific rigor to the study’s claims.
From this analysis, researchers identified 19 conditions showing a clear genetic association with Alzheimer’s disease — either through individual genomic risk variants or through a polygenic risk score specific to Alzheimer’s. This means these conditions don’t just co-occur with Alzheimer’s; they also share genetic underpinnings.
What Genetic Overlap Means
While EHR-based associations do not prove causation, the convergence of health record patterns and genetic data creates a compelling foundation for future research. Together, they provide what the authors describe as a “data-driven road map” for earlier risk recognition.
The Cancer–Alzheimer’s Inverse Link
One of the more surprising findings involves cancer. The study found an inverse association between cancer and Alzheimer’s disease — meaning patients diagnosed with cancer appeared less likely to develop Alzheimer’s later. This pattern replicates previous findings in the literature and adds further weight to the biological connection.
Researchers have theorized this may relate to shared but opposing cellular mechanisms. Specifically, cancer involves uncontrolled cell growth, while Alzheimer’s involves cell death. Further investigation into this relationship could yield new insights for therapeutic development.
What This Means for Patient Care
A Practical Tool for Clinicians
Longitudinal EHRs give clinicians a powerful diagnostic lens. Rather than waiting for memory loss to trigger evaluation, providers can use this evidence base to flag patients with multiple known precursor conditions. Depression combined with hypertension and insomnia, for example, may warrant earlier cognitive screening.
“Longitudinal EHRs offer a powerful view into the decades-long development of Alzheimer’s disease,” said Dr. Zhong. “By identifying medical patterns that consistently precede the disease, we can unlock new opportunities for risk reduction, early intervention, and improved patient outcomes.”
Managing Modifiable Risk Factors
Importantly, many of the conditions identified — such as hypertension, Type 2 diabetes, and hyperlipidemia — are modifiable. Patients and clinicians can take action on these factors right now. Lifestyle changes, medication management, and routine monitoring all represent accessible entry points for reducing long-term risk.
Moving Forward in Prevention Research
From Data Patterns to Clinical Protocols
The next step involves translating these findings into clinical protocols. Specifically, healthcare systems can develop automated EHR flags that alert providers when patients display multiple precursor conditions. Additionally, researchers can use this condition inventory as a roadmap for designing intervention trials.
Furthermore, the study opens new avenues for genetic research. Since 19 of the identified conditions share a genetic basis with Alzheimer’s, pharmaceutical developers may find new targets for drug development. Prevention-focused clinical trials can now prioritize patients with the highest genetic and clinical risk profiles.
A Scalable, Replicable Approach
Because the methodology relies on de-identified EHR data from large, established databases, it is both scalable and replicable. Other health systems around the world can apply similar approaches to their patient populations. As a result, this research model could expand the global understanding of Alzheimer’s risk factors across diverse demographics and geographies.
